11,764,000 Shares in RAPT Therapeutics, Inc. (NASDAQ:RAPT) Acquired by RTW Investments LP

RTW Investments LP purchased a new position in shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 11,764,000 shares of the company’s stock, valued at approximately $18,587,000. RTW Investments LP owned approximately 33.65% of RAPT Therapeutics at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in RAPT. Barclays PLC boosted its position in RAPT Therapeutics by 277.2% in the third quarter. Barclays PLC now owns 39,729 shares of the company’s stock valued at $79,000 after buying an additional 29,195 shares in the last quarter. JPMorgan Chase & Co. boosted its position in RAPT Therapeutics by 298.2% in the third quarter. JPMorgan Chase & Co. now owns 16,703 shares of the company’s stock valued at $34,000 after buying an additional 25,130 shares in the last quarter. SG Americas Securities LLC boosted its position in RAPT Therapeutics by 401.9% in the fourth quarter. SG Americas Securities LLC now owns 53,244 shares of the company’s stock valued at $84,000 after buying an additional 42,636 shares in the last quarter. Medicxi Ventures Management Jersey Ltd acquired a new stake in RAPT Therapeutics in the fourth quarter valued at approximately $35,316,000. Finally, Los Angeles Capital Management LLC boosted its position in RAPT Therapeutics by 9.2% in the fourth quarter. Los Angeles Capital Management LLC now owns 219,997 shares of the company’s stock valued at $348,000 after buying an additional 18,558 shares in the last quarter. Institutional investors and hedge funds own 99.09% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “buy” rating and issued a $10.00 target price on shares of RAPT Therapeutics in a research report on Monday, March 10th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat, RAPT Therapeutics currently has a consensus rating of “Hold” and a consensus target price of $4.00.

RAPT Therapeutics Stock Performance

RAPT stock opened at $0.81 on Friday. The company has a fifty day moving average price of $1.00 and a 200-day moving average price of $1.23. The company has a market capitalization of $107.01 million, a P/E ratio of -0.29 and a beta of -0.04. RAPT Therapeutics, Inc. has a 52-week low of $0.71 and a 52-week high of $4.83.

RAPT Therapeutics (NASDAQ:RAPT) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.31) by $0.23. As a group, sell-side analysts forecast that RAPT Therapeutics, Inc. will post -2.14 earnings per share for the current fiscal year.

RAPT Therapeutics Company Profile

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.